CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net revenue	[1]	$ 30,262	$ 25,639
Cost of revenue		9,103	9,004
Gross profit		21,159	16,635
Operating expenses:
Research, development and clinical trials		22,304	18,831
Selling, general and administrative		38,283	24,188
Total operating expenses		60,587	43,019
Loss from operations		(39,428)	(26,384)
Other income (expense):
Interest expense		(3,874)	(3,985)
Other income (expense), net		(877)	1,653
Total other expense, net		(4,751)	(2,332)
Loss before income taxes		(44,179)	(28,716)
Provision for income taxes		(36)	(32)
Net loss		$ (44,215)	$ (28,748)
Net loss per share attributable to common stockholders, basic		$ (1.60)	$ (1.16)
Net loss per share attributable to common stockholders, diluted		$ (1.60)	$ (1.16)
Weighted average common shares outstanding, basic		27,616,839	24,702,764
Weighted average common shares outstanding, diluted		27,616,839	24,702,764

[1] Net revenue by country is categorized based on the location of the end customer